Search

Latest guidance from NICE

Standard post

… (CLL), axicabtagene ciloleucel for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mosunetzumab for relapsed or refractory follicular lymphoma and axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. Ibrutinib recommended for CLL …

CAR T-cell therapy Yescarta® not available in Scotland

Standard post

… large B cell lymphoma (PMBCL) that has not responded ( refractory ) or has come back ( relapsed ) after two or more … offers a potential lifeline for people with relapsed or refractory DLBCL or PMBCL, who otherwise have extremely … will be available in Scotland for people with relapsed or refractory DLBCL on 11 March. It has already approved …

Tafasitamab with lenalidomide not recommended

Standard post

… tafasitamab with lenalidomide for treating relapsed or refractory (R/R)  diffuse large B-cell lymphoma (DLBCL)  in … basis for the treatment of adult patients with relapsed or refractory DLBCL who are not candidates for ASCTs. CAR T-cell … are also licensed and approved by SMC for relapsed or refractory DLBCL, after two or more lines of systemic …

NHS consultation on bendamustine with rituximab

Standard post

… of the efficacy of bendamustine plus rituximab in relapsed/refractory indolent NHL. Bendamustine plus rituximab compares … chemotherapy regimens in the frontline and relapsed/refractory setting (Marcus R et al. J Clin Oncol … obinutuzumab is more effective than bendamustine alone in refractory indolent NHL (Sehn LH et al, Lancet Oncology …

Positive early results for CAR T-cell therapy in mantle cell lymphoma

Standard post

… lymphoma that has come back (relapsed) or not responded (refractory) to previous treatment. Mantle cell lymphoma is a … are already available for some people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or primary … a promising treatment option for people with relapsed or refractory mantle cell lymphoma. It is being studied in …

More good news around CAR T-cell therapy

Standard post

… leukaemia (ALL) that has not responded to treatment (refractory) or has come back (relapsed) after a stem cell … currently evaluating Kymriah for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In its …

Highlights from BSH

Standard post

… could be a promising treatment option for relapsed or refractory low-grade non-Hodgkin lymphoma. High-grade … a drug called pirtobrutinib in people with relapsed or refractory B-cell non-Hodgkin lymphomas , CLL or SLL . Early … a tablet once a day. So far, 170 people with relapsed or refractory CLL/SLL have joined the BRUIN trial. On average, …

Results of new antibody treatment for Sézary syndrome

Standard post

… that had come back (relapsed) or had not responded (refractory) to previous treatment. Most of the people who … found that IPH4102 was safe in people with relapsed or refractory T-cell skin lymphoma. The most common side effects …

Clinical trials update from the 15th ICML

Standard post

… treatment with vorinostat for people with relapsed or refractory T-cell skin lymphomas . It was granted a European … licence for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome in November … study showed that around 2 in 3 people with relapsed or refractory extranodal NK/T-cell lymphoma responded to …